# Rexaceract PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/rexaceract

> The next catalyst for rexaceract, sponsored by Gain Therapeutics, Inc. (GANX), is its trial start, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for rexaceract?

The next catalyst for rexaceract, sponsored by Gain Therapeutics, Inc. (GANX), is its trial start, Q1 2027. Press release filed with the SEC (EX-99): "Initiation of rexaceract Phase 2 clinical trial expected during Q1 2027 following a comprehensive redesign and submission of new Phase 2 protocol." [Calendar and source filings](https://sec-api.dev/pdufa/rexaceract)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-125159, https://www.sec.gov/Archives/edgar/data/1819411/000110465926125159/ganx-ex99d1.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/pdufa/rexaceract#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | rexaceract |
| Codes |  |
| Sponsor | Gain Therapeutics, Inc. (GANX) https://sec-api.dev/companies/ganx/catalysts |
| Indications | [parkinson's disease](https://sec-api.dev/indications/parkinson-s-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Q3 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Parkinson's disease.
- First seen 2026-08-11, last confirmed 2026-08-11.
- SEC Form 10-Q (accession 0001104659-26-094048): "In June 2026, The Company has received Investigational New Drug (IND) authorization from the FDA to commence a Phase 2 study of rexaceract in people with Parkinson's disease, anticipated to begin in the third quarter of 2026 across sites in the United States, Australia, and Europe." https://www.sec.gov/Archives/edgar/data/1819411/000110465926094048/ganx-20260630x10q.htm

### Q1 2027: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Parkinson's disease.
- First seen 2026-11-10, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-125159): "Initiation of rexaceract Phase 2 clinical trial expected during Q1 2027 following a comprehensive redesign and submission of new Phase 2 protocol." https://www.sec.gov/Archives/edgar/data/1819411/000110465926125159/ganx-ex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-125167): "In June 2026, the Company received Investigational New Drug (IND) authorization from the FDA to commence a Phase 2 study of rexaceract in people with Parkinson's disease, anticipated to begin in the first quarter of 2027 across sites in the United States, Australia, and Europe." https://www.sec.gov/Archives/edgar/data/1819411/000110465926125167/ganx-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-125167): "In June 2026, we received Investigational New Drug (IND) authorization from the FDA to commence a Phase 2 study of rexaceract in people with Parkinson's disease, anticipated to begin in the first quarter of 2027 across sites in the United States, Australia, and Europe." https://www.sec.gov/Archives/edgar/data/1819411/000110465926125167/ganx-20260930x10q.htm

## Same indication

- [ARV-102](https://sec-api.dev/pdufa/arv-102) (ARVN)
- [Envudeucitinib](https://sec-api.dev/pdufa/envudeucitinib) (ALMS)
- [Juvmo (tavapadon)](https://sec-api.dev/pdufa/tavapadon) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/rexaceract.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Rexaceract PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/rexaceract

```bibtex
@misc{secapidev_pdufa_rexaceract_20261116,
  title        = {Rexaceract PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/rexaceract}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_rexaceract_20261116","title":"Rexaceract PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/rexaceract","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
